

## Vidaza (azacitidine)

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do\_not\_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date:
Patient's ID:		Patient's Date of Birth:
Physician's Name:		
Specialty:		NPI#:
Physician Office Telephone:		Physician Office Fax:
<b>Referring</b> Provider Info: ☐ Same as Ro	equesting Provi	der
Name:		NPI#:
Fax:		Phone:
Rendering Provider Info: ☐ Same as Romane:	_	
Fax:		Phone:
11 0		s in accordance with FDA-approved labeling, vidence-based practice guidelines.
Patient Weight:	kg	
Patient Height:	cm	
Please indicate the place of service for the	e requested drug	:
☐ Ambulatory Surgical	$\square$ Home	☐ Off Campus Outpatient Hospital
On Campus Outpatient Hospital	<b>□</b> Office	☐ Pharmacy

Criteria Questions:
A. What is the prescribed drug? ☐ Vidaza ☐ azacitidine ☐ Other
B. What is the ICD-10 code?
1. What is the diagnosis?
☐ Myelodysplastic syndrome (MDS) (If checked, go to 2)
☐ Acute myeloid leukemia (AML) (If checked, go to 2)
☐ Accelerated phase or blast phase myelofibrosis ( <i>If checked, go to 2</i> )
☐ Blastic plasmacytoid dendritic cell neoplasm (BPDCN) ( <i>If checked, go to 4</i> ) ☐ Myelodysplastic syndrome (MDS)/Myeloproliferative Neoplasms (MPN) Overlap Neoplasms (i.e. chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), BCR-ABL negative atypica chronic myeloid leukemia (aCML), MDS/MPN with neutrophilia, unclassifiable MDS/MPN, or MDS/MPN with ring sideroblasts and thrombocytosis) ( <i>If checked, go to 2</i> )
☐ Other, please specify (If checked, no further questions)
<ul> <li>2. Is the patient currently receiving treatment with the requested medication?</li> <li>☐ Yes, Continue to 3</li> <li>☐ No, No Further Questions</li> </ul>
3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?  ☐ Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>
<ul> <li>4. Is the patient currently receiving treatment with the requested medication?</li> <li>☐ Yes, Continue to 5</li> <li>☐ No, Continue to 6</li> </ul>
5. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?  ☐ Yes, No Further Questions ☐ No, No Further Questions
<ul> <li>6. Does the patient have relapsed or recurrent disease?</li> <li>☐ Yes, Continue to 8</li> <li>☐ No, Continue to 7</li> </ul>
<ul> <li>7. Is the requested drug being used for systemic disease with palliative intent?</li> <li>☐ Yes, Continue to 8</li> <li>☐ No, Continue to 8</li> </ul>
8. Will the requested medication be used in combination with venetoclax (Venclexta)?  ☐ Yes, No Further Questions ☐ No, No Further Questions
I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.
X

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Vidaza [azacitidine] SGM 2280-A - 07.2023.